CM-Path Strategic Vision
CM-Path is committed to supporting the TRAINING of all pathologists at all stages in their careers in order to produce a workforce with the skills necessary to maximise the benefits of new research findings for the treatment of cancer patients.
- Contribute to the development of the new RCPath postgraduate curriculum – Dr Nick West (CM-Path WS1 member) and Dr Kathryn Griffin (CM-Path WS1 Trainee member) sit on the RCPath Curriculum Working Group.
- In association with RCPath and HEE, deliver interim training in Molecular Pathology until the new postgraduate curriculum comes into effect. Our first workshop of this type is on the 17th and 18th July 2019.
- Deliver a structured training programme for pathologists in Clinical Trials.
- Deliver training for pathologists in their role in GTAB’s.
CM-Path will ensure that pathology expertise is available to drive and deliver high quality pathology contribution to clinical TRIALS. We will work to enable pathologists to be involved appropriately from trial development onwards.
- SPIRIT-Path Extension: Project to deliver international consensus guidance on the inclusion of pathology in clinical trial protocols.
- Develop the CT-PAG to ensure pathology is built into trials early in trial development and to advise on tissue handling, biomarker and translational aspects of trial development.
CM-Path will share practice and develop solutions to support pathologists to have TIME in their job plans to develop and deliver clinical and translational studies as well as other academic activity.
- Propose changes to the NIHR commercial costing template and the HRA Schedule of events to include more pathology activities. To ensure that pathology is costed for appropriately in trials.
- Investigate launching new funding themed calls in molecular pathology with funding bodies such as NIHR/MRC to allow pathologists funding and time in their job plans to deliver research.
CM-Path is committed to promoting tissue-based research, facilitating access to good quality TISSUE samples which are suitable to analysis using new and emerging technology and building and enabling quality supporting infrastructure.
- Relaunch the Confederation of Cancer Biobanks.
- Create a template Consent Form and Patient information sheet to reduce regulatory burden on researchers and biobanks.
- Promote uptake of CM-Path Biobanking sample quality improvement tool.
CM-Path will support pathologist to gain expertise in, evaluate and deliver appropriate novel pathology TESTS, TECHNOLOGICAL SOLUTIONS and integrated diagnostics.
- Engage with NHSE to define pathology involvement in the ongoing evaluation, management and updates of the genomic test directory
- Plan and execute an integrated diagnostics workshop on ‘’the pathology report of the future’’ (to aid understanding of the medium-to-long term overarching vision, so as to help co-ordinated planning, prioritisation and delivery of digital pathology and molecular diagnostics)
- Engage with PPI to gauge the understanding and views on public perception of cellular pathology and working with industrial partners in order to create such image analysis/AI tools. We would like to understand what educational or engagement materials could be created and be most effective and also how we should convey the messages about the need to work with industry.
CM-Path will deliver a TRANSITION plan by March 2020 for consideration by the NCRI Strategy Advisory Group and NCRI Funding partners to ensure that the NCRI does not lose the valuable ideas in, knowledge of, position with and understanding of the pathology discipline that it has gained through CM-Path.
- Deliver a strategic vision for CM-Path beyond 2021 and submit as a funding proposal to the NCRI by March 2020.